Clinical Trial Update: Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase II trial investigating dasatinib in IDH-mutant advanced intrahepatic cholangiocarcinoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Cholangiocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-07-31